Brentuximab vedotin in relapsed/refractory Hodgkin’s lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials

Clinical trial results indicate that brentuximab vedotin brings considerable promise for the treatment of patients with relapsed or refractory Hodgkin’s lymphoma. A retrospective multicenter study was conducted on 65 heavily pretreated patients who underwent therapy through a Named Patient Program i...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Zinzani, Pier Luigi, Viviani, Simonetta, Anastasia, Antonella, Vitolo, Umberto, Luminari, Stefano, Zaja, Francesco, Corradini, Paolo, Spina, Michele, Brusamolino, Ercole, Gianni, Alessandro M., Santoro, Armando, Botto, Barbara, Derenzini, Enrico, Pellegrini, Cinzia, Argnani, Lisa
Format: Artigo
Jezik:Inglês
Izdano: Ferrata Storti Foundation 2013
Teme:
Original Articles and Brief Reports
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3729903/
https://ncbi.nlm.nih.gov/pubmed/23645687
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2012.083048
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items